Back to results
US 11,072,781 B2Granted
Genomic engineering of pluripotent cells
AssigneeFate Therapeutics, Inc.
InventorsBahram Valamehr, Ramzey Abujarour, Tom Tong Lee, Weijie Lan, Raedun Clarke, Ryan Bjordahl
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for obtaining genome-engineered iPSCs, and derivative cells with stable and functional genome editing at selected sites. Also provided are cell populations or clonal cell lines derived from genome-engineered iPSCs, which comprise targeted integration of one or more exogenous polynucleotides, and/or in/dels in one or more selected endogenous genes.
Claims18
An induced pluripotent cell (iPSC) derived cell or a population thereof, wherein (i) the iPSC-derived cell is a hematopoietic lineage cell differentiated from an iPSC;
- (ii) the iPSC-derived cell comprises a polynucleotide encoding at least one chimeric antigen receptor (CAR) introduced into a constant region of a T cell receptor (TCR) locus, wherein the at least one CAR is expressed in the iPSC-derived cell;
- (iii) an endogenous TCR gene of the iPSC-derived cell is knocked out;
- (iv) the iPSC-derived cell comprises introduced or increased expression of CD16;
- and (v) the iPSC-derived cell further comprises:
- (a) a deletion or reduced expression of at least one of B2M and/or CIITA genes;
- or
- (b) introduced or increased expression of CD3.
4 more elements
Dependencies are inferred from the claim text.